- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06211868
Redirecting Immune, Lipid and Metabolic Drivers of Early Cardiovascular Disease: The RESET Cohort Study (RESET)
October 10, 2024 updated by: National University Hospital, Singapore
Project RESET is a Singapore National Medical Research Council Large Collaborative Grant funded program that brings together a nationwide community of cardiovascular, metabolic, and digital health researchers, as well as clinicians across primary and tertiary care to study the immune, lipid and metabolic drivers of early cardiovascular disease.
RESET incorporates a nested randomised controlled trials (RCT) to test the use of a combined digital wearable and AI-human symbiotic lifestyle intervention to halt or reverse the progression of early disease.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
3000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hayang Yang, PhD
- Phone Number: +6582810448
- Email: h.yang@nus.edu.sg
Study Locations
-
-
-
Singapore, Singapore
- Recruiting
- NUS
-
Contact:
- Hayang Yang, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Sampling Method
Non-Probability Sample
Study Population
South-East Asian population aged 40-70 years with no prior manifest atherosclerotic cardiovascular disease (ACSVD).
Description
Inclusion Criteria:
- 40-70 years old
- ASCVD (atherosclerotic cardiovascular disease) score of 5% and higher
Exclusion Criteria:
- Previous major cardiovascular disease (myocardial infarction, heart failure, ischemic stroke)
- Limited life expectancy
- Other ongoing unstable medical conditions
- Pregnant women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Observational cohort
|
|
|
Randomised cohort
|
Digital wearable and AI-human symbiotic lifestyle intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Major adverse cardiovascular event
Time Frame: 5 years
|
Composite of cardiac death, non-fatal myocardial infarction, resuscitated cardiac arrest, non-fatal ischemic stroke, congestive heart failure, coronary revascularization
|
5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2024
Primary Completion (Estimated)
September 1, 2029
Study Completion (Estimated)
September 1, 2030
Study Registration Dates
First Submitted
December 6, 2023
First Submitted That Met QC Criteria
January 16, 2024
First Posted (Actual)
January 18, 2024
Study Record Updates
Last Update Posted (Actual)
October 15, 2024
Last Update Submitted That Met QC Criteria
October 10, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RESET (Alias Study Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.